Menu
No results found.
Weekly Share Price & Valuation Overview
Shanghai Haohai Biological Technology Co., Ltd.
Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in China, Europe, the United States, and internationally. It offers ophthalmology products consist of intraocular lens, medical sodium hyaluronate gel, and lubricant eye drop. The company also offers sodium hyaluronate injection, medical chitosan, medical sodium hyaluronate gel, anti-adhesion, and burn wound related products. In addition, it provides injectors, scalpels, suture needles and other products. Further, the company offers medical aesthetics products, including Matrifill, a first-generation hyaluronic acid (HA) dermal filler, which is a mono-phase sodium hyaluronate gel for injection; Janlane, a second-generation HA dermal filler for dynamic filling function; Hyalumatrix, a third-generation HA dermal filler that offers precise embellishment function; genetic-engineering preparations for epidermal repair; and radio frequency devices and laser equipment. Additionally, it is involved in the research and development, consultation, and services of biological engineering and pharmaceutical products, and related technology transfer activities; manufacture and sale of biological reagents, biologicals, and biological materials; manufacture and sale of intraocular lens and related products; sale machines of medical aesthetics, professional life cosmetology, and home cosmetology; sale of ophthalmology products; and provision of other machines and accessories. The company was formerly known as Haohai Limited and changed its name to Shanghai Haohai Biological Technology Co., Ltd. in 2010. Shanghai Haohai Biological Technology Co., Ltd. was founded in 2007 and is headquartered in Shanghai, China.
- Healthy operating margin (≥15%) indicates efficient core operations.
- High gross margin (≥35%) suggests strong pricing power or cost control.
- Double-digit profit margin (≥10%) supports robust bottom-line economics.
- Quick ratio ≥1.0 indicates obligations can be met without inventory.
- Net cash balance sheet provides flexibility for downturns and investment.
- Market Cap Total equity value of the company (share price × shares outstanding).
- HKD 12.58B
- Enterprise Value Operating value: market cap + total debt − cash.
- HKD 4.84B
- Total Revenue (TTM) Estimated Sales over the last twelve months. May be estimated from revenue per share when inconsistent.
- HKD 438.69M
- Gross Profit (TTM) Revenue minus cost of goods sold over the last twelve months. Hidden for financial institutions or if redundant.
- HKD 1.82B
- Revenue per Share (TTM) Total revenue divided by shares outstanding (may be estimated).
- HKD 11.39
- EPS (TTM) Earnings per share over the last twelve months (may be estimated from net income ÷ shares).
- 1.97
- Dividend Yield Annual dividend ÷ share price. Reconciled using dividend per share when available.
- 3.74%
- Shares Outstanding
- 38.53M
- Float Shares
- 77.62M
- Implied Shares Outstanding
- 430.41M
- Operating Margin (TTM) Strong Operating income ÷ revenue over the last twelve months (reconciled when possible).
-
15.74%
- Gross Margin (TTM) Reconciled Strong Gross profit ÷ revenue over the last twelve months (reconciled when possible).
-
414.74%
- Profit Margin (TTM) Solid Net income ÷ revenue over the last twelve months (reconciled when possible).
-
15.58%
- ROA Return on assets: net income ÷ total assets.
-
3.22%
- ROE Return on equity: net income ÷ shareholder equity.
-
6.09%
- Revenue Growth Year-over-year revenue growth.
-
-4.30%
- Earnings Growth (YoY) Year-over-year earnings growth.
-
-7.10%
- Earnings Growth (QoQ) Quarter-over-quarter earnings growth.
-
-7.40%
- Quick Ratio Adequate Liquid current assets ÷ current liabilities (ex-inventory).
- 3.58
- Debt to Equity Total debt ÷ shareholder equity; leverage.
- 0.08
- Total Cash Cash and equivalents.
- HKD 2.66B
- Total Debt Short + long-term interest-bearing debt.
- HKD 452.51M
- Net Debt Net Cash Total debt − cash (negative = net cash).
- HKD -2.21B
- Free Cash Flow (TTM) Cash after capex; funds buybacks, dividends, and debt paydown.
- HKD 247.88M
- FCF Margin (TTM) Free cash flow ÷ revenue (TTM).
-
56.51%
- Total Revenue (TTM) estimated from Revenue per Share × Shares due to feed inconsistency.
- EBITDA & EBITDA margin suppressed (implausible vs revenue or not meaningful for financials).
- Margins shown on a TTM basis. “Reconciled” = numerator ÷ TTM revenue for internal consistency.
- Cash Flow section is displayed only when figures are self-consistent (and hidden for financials).
Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.